You are here:

valganciclovir (Valcyte)


Following an abbreviated submission

valganciclovir powder for 50mg/ml oral solution (Valcyte) is accepted for restricted use in NHS Scotland for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).

Its use should be under the overall supervision of an expert ophthalmologist and a physician experienced in the management of HIV / AIDS patients. In patients for whom valganciclovir is an appropriate choice of therapy this is the only licensed formulation for those undergoing haemodialysis (creatinine clearance <10ml/minute). Otherwise its use should be restricted to patients unable to use the less costly solid oral dosage form.

Drug Details

Drug Name: valganciclovir (Valcyte)
SMC Drug ID: 586/09
Manufacturer: Roche
Indication: Solid Organ Transplantation / AIDS
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 7 December 2009